Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide

Abstract

The presence of renal noninflammatory necrotizing vasculopathy (NNV) is often associated with a severe form of lupus nephritis (LN), which is unresponsive to standard therapy. We conducted a 6-month randomized, prospective, open-label trial comparing mycophenolate mofetil (MMF) (1.5—2.0 g/day) with monthly i.v. cyclophosphamide (CTX) (0.75—1.0 g/m2) as induction therapy for class IV LN with NNV. The primary and second end points were complete remission (CR) and partial remission (PR), respectively. Of 20 patients recruited, nine were randomly assigned to MMF and 11 to CTX. The baseline characteristics between groups were not significant. CR was achieved in four patients (44.4%) receiving MMF and in none of the patients receiving CTX (P = 0.026). PR was achieved in two patients (22.2%) in the MMF group and three patients (27.2%) in the CTX group. The total remission rate (CR + PR) in the MMF and CTX group was 66.6 and 27.2%, respectively (P = 0.17). MMF was more effective than i.v. CTX in reducing proteinuria and haematuria. Adverse events were significantly less frequent with MMF than with CTX (P = 0.028). MMF was superior to i.v. CTX in inducing CR of LN with NNV and had a more favourable safety profile. Lupus (2007) 16, 707—712.

Keywords

cyclophosphamide lupus nephritis mycophenolate mofetil noninflammatory necrotizing vasculopathy treatment

Get full access to this article

View all access options for this article.

References

Appel GB , Pirani CL, D'Agati. Renal vascular complications of systemic lupus erythematosus . J Am Soc Nephrol 1994; 4: 1499—1515.

Banfi G. , Bertani F. , Boen V. et al. Renal vascular lesions as a marker of a poor prognosis in patients with LN. Am J Kidney Dis 1991; 18: 240—248.

Yao G. , Hu WX , Liu ZH et al. The significance of renal vascular lesion in patients with proliferative lupus nephritis. J Nephrol Dialy Transplant 2002; 11: 211—217.

Bhathena DB , Sobel BJ , Migdal SD Noninflammatory renal microangiopathy of systemic lupus erythematosus (`lupus vasculitis'). Am J Nephrol 1981; 1: 144—159.

Sung JM , Hsu SC , Chen FF et al. Systemic lupus erythematosus presented as non-inflammatory necrotizing vasculopathy-induced ischemic glomerulopathy and small vessels-related ischemic cardiomyopathy. Lupus 2002; 11: 458—462.

Grishman E. , Venkataseshan VS Vascular lesions in LN. Mod Pathol 1988; 1: 235—241.

Steinberg AD , Steinberg SC Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945—950.

Ioannidis Jpa , Boki KA , Katsorida EM et al. Remission, relapse and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258—264.

Mok CC , Ying KY , Tang S. et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559—2568.

10.

Cortes-Hernandez J. , Ordi-Rios J. , Labrador M. et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287—296.

11.

Gaubitz M. , Schorat A. , Schotte H. et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731—736.

12.

Kingdon EJ , McLean AG , Psimenou E. et al. The safety and efficacy of MMF in lupus nephritis: a pilot study . Lupus 2001; 10: 606 —611.

13.

Hu WX , Liu ZH , Chen HP et al. MMF vs. cyclophosphamide therapy for patients with diffuse proliferative LN. Chin Med J (Engl) 2002; 115: 705—709.

14.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271—1277.

15.

Weening JJ , D'agati VD , Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241—250.

16.

Austin HA Iii , Muenz LR , Joyce KM et al. Diffuse proliferative LN: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689—695.

17.

Descombes E. , Droz D. , Drouet L. et al. Renal vascular lesions in LN. Medicine (Baltimore) 1997; 76: 355—368.

18.

Chien-Te W. , Lin-Shien F. Lupus vasculopathy combined with acute renal failure in LN. Pediatr Nephrol 2003; 18: 1304—1307.

19.

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156—1162.

20.

Gaubitz M. , Schorat A. , Schotte H. et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731—736.

21.

Flores-Suarez LF Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil. Arch Med Res 2006; 37: 68—73.